318 related articles for article (PubMed ID: 10529127)
21. Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial.
Lü LJ; Teng JL; Bao CD; Han XH; Sun LY; Xu JH; Li XF; Wu HX
Chin Med J (Engl); 2008 Apr; 121(7):615-9. PubMed ID: 18466681
[TBL] [Abstract][Full Text] [Related]
22. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis.
Williams HJ; Ward JR; Dahl SL; Clegg DO; Willkens RF; Oglesby T; Weisman MH; Schlegel S; Michaels RM; Luggen ME
Arthritis Rheum; 1988 Jun; 31(6):702-13. PubMed ID: 2898244
[TBL] [Abstract][Full Text] [Related]
23. Sulfasalazine therapy for juvenile rheumatoid arthritis.
Imundo LF; Jacobs JC
J Rheumatol; 1996 Feb; 23(2):360-6. PubMed ID: 8882047
[TBL] [Abstract][Full Text] [Related]
24. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists.
Pope JE; Hong P; Koehler BE
J Rheumatol; 2002 Feb; 29(2):255-60. PubMed ID: 11838842
[TBL] [Abstract][Full Text] [Related]
25. Methotrexate therapy in rheumatoid arthritis after failure to sulphasalazine: to switch or to add?
Schipper LG; Fransen J; Barrera P; den Broeder AA; Van Riel PL
Rheumatology (Oxford); 2009 Oct; 48(10):1247-53. PubMed ID: 19638454
[TBL] [Abstract][Full Text] [Related]
26. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or american college of rheumatology criteria for remission.
Sokka T; Pincus T
J Rheumatol; 2003 Jun; 30(6):1138-46. PubMed ID: 12784382
[TBL] [Abstract][Full Text] [Related]
27. Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases.
Ujfalussy I; Koó E; Seszták M; Gergely P
Z Rheumatol; 2003 Apr; 62(2):155-60. PubMed ID: 12721703
[TBL] [Abstract][Full Text] [Related]
28. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs.
Maetzel A; Wong A; Strand V; Tugwell P; Wells G; Bombardier C
Rheumatology (Oxford); 2000 Sep; 39(9):975-81. PubMed ID: 10986302
[TBL] [Abstract][Full Text] [Related]
29. Treatment continuation rate in relation to efficacy and toxicity in long-term therapy with low-dose methotrexate, sulfasalazine, and bucillamine in 1,358 Japanese patients with rheumatoid arthritis.
Nagashima M; Matsuoka T; Saitoh K; Koyama T; Kikuchi O; Yoshino S
Clin Exp Rheumatol; 2006; 24(3):260-7. PubMed ID: 16870092
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of sulphasalazine plus methotrexate in rheumatoid arthritis.
Islam MN; Alam MN; Haq SA; Moyenuzzaman M; Patwary MI; Rahman MH
Bangladesh Med Res Counc Bull; 2000 Apr; 26(1):1-7. PubMed ID: 11192489
[TBL] [Abstract][Full Text] [Related]
31. Comparisons of sulfasalazine to gold and placebo in the treatment of rheumatoid arthritis.
Williams HJ
J Rheumatol Suppl; 1988 Sep; 16():9-13. PubMed ID: 2903928
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study.
Aletaha D; Smolen JS
J Rheumatol; 2002 Aug; 29(8):1631-8. PubMed ID: 12180721
[TBL] [Abstract][Full Text] [Related]
33. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis.
Strand V; Scott DL; Emery P; Kalden JR; Smolen JS; Cannon GW; Tugwell P; Crawford B;
J Rheumatol; 2005 Apr; 32(4):590-601. PubMed ID: 15801012
[TBL] [Abstract][Full Text] [Related]
34. Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis.
Jansen G; van der Heijden J; Oerlemans R; Lems WF; Ifergan I; Scheper RJ; Assaraf YG; Dijkmans BA
Arthritis Rheum; 2004 Jul; 50(7):2130-9. PubMed ID: 15248210
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled study.
Gibofsky A; Rodrigues J; Fiechtner J; Berger M; Pan S
Clin Ther; 2007 Jun; 29(6):1071-85. PubMed ID: 17692722
[TBL] [Abstract][Full Text] [Related]
36. Sulfasalazine for ankylosing spondylitis.
Chen J; Liu C
Cochrane Database Syst Rev; 2005 Apr; (2):CD004800. PubMed ID: 15846731
[TBL] [Abstract][Full Text] [Related]
37. Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials.
Chen J; Liu C
J Rheumatol; 2006 Apr; 33(4):722-31. PubMed ID: 16583475
[TBL] [Abstract][Full Text] [Related]
38. Intention-to-treat analysis of 200 patients with rheumatoid arthritis 12 years after random allocation to either sulfasalazine or penicillamine.
Capell HA; Maiden N; Madhok R; Hampson R; Thomson EA
J Rheumatol; 1998 Oct; 25(10):1880-6. PubMed ID: 9779839
[TBL] [Abstract][Full Text] [Related]
39. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
[TBL] [Abstract][Full Text] [Related]
40. Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trial.
Lee EY; Lee EB; Park BJ; Lee CK; Yoo B; Lim MK; Shim SC; Sheen DH; Seo YI; Kim HA; Baek HJ; Song YW
Clin Ther; 2006 Dec; 28(12):2052-60. PubMed ID: 17296461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
